Therapuetic fusion proteins have emerged as a new option for biologics. Their improved pharmacokinetic stability and enhanced capability to act on two or more molecular targets make them a popular choice for future drug development.
Read this white paper to explore fusion protein drug R&D trends identified by a collaboration between CAS analytics experts and the National Science Library of the Chinese Academy of Sciences.
